Oxcarbazepine Tablet, Film Coated
Product Images NDC 62559-222

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 62559-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Logo (Ani)

FDA Label Image

Fig-1 (Fig 1)

A Kaplan-Meier survival curve graph showing the exit rate over time on trial from Day 2 to Day 11 for two treatment groups: Oxcarbazepine and Placebo. The graph includes a log-rank test p-value of 0.0001, indicating a statistical comparison between the treatments.*

FDA Label Image

Fig-2 (Fig 2)

A Kaplan-Meier curve chart showing seizure rate over days from first dose. The plot compares two treatment groups: medication (solid line) and placebo (dotted line). The y-axis reflects seizure rate from 0 to 1, and the x-axis shows days from 0 to 140. A log-rank test p-value of 0.046 is displayed, indicating a statistically significant difference between groups.*

FDA Label Image

Fig-3 (Fig 3)

A Kaplan-Meier survival plot displaying exit rates over time (days) for two treatment groups labeled HIGH and LOW. The x-axis shows time to exit in days, and the y-axis represents exit rate. A log-rank test with a p-value of 0.0001 is indicated on the graph.*

FDA Label Image

Fig-4 (Fig 4)

A Kaplan-Meier survival curve chart illustrating the time to exit (days) for two treatment groups, labeled HIGH and LOW. The y-axis represents the exit rate from 0.0 to 1.0, and the x-axis shows time to exit in days, ranging from 0 to 130. The chart includes a log-rank test p-value of 0.0001.*

FDA Label Image

Label-2 (Label 2)

Oxcarbazepine Tablets USP 150 mg film-coated tablets label from ANI Pharmaceuticals, Inc. The label shows a 500-tablet count with storage instructions, NDC 62559-220-05, and mentions dispensing the accompanying Medication Guide. Manufactured by Esjay Pharma Private Limited, India.*

FDA Label Image

Label-3 (Label 3)

Label for Oxcarbazepine Tablets USP 300 mg in a 100 count package. The film-coated oral tablets are distributed by ANI Pharmaceuticals, Inc. The label includes storage instructions, a barcode, and mentions manufacturing by Esjay Pharma Private Limited in India. The label also advises pharmacists to dispense the Medication Guide to patients.*

FDA Label Image

Label-4 (Label 4)

Oxcarbazepine Tablets USP 300 mg film-coated tablets packaging label. The label indicates 500 tablets, prescription only, distributed by ANI Pharmaceuticals, Inc. The label includes storage instructions, child-resistant packaging notice, and manufacturer details: Esjay Pharma Private Limited, India. The Ani Pharmaceuticals logo appears at the bottom left.*

FDA Label Image

Label-5 (Label 5)

Oxcarbazepine Tablets USP 600 mg oral film-coated tablets packaging label. Contains 100 tablets and is labeled for prescription use only. The label includes storage instructions, manufacturer Esjay Pharma Private Limited (India), and distributor ANI Pharmaceuticals, Inc. (Baudette, MN). The label features the ANI Pharmaceuticals logo and a barcode.*

FDA Label Image

Label-6 (Label 6)

Label for Oxcarbazepine Tablets USP 600 mg, film-coated oral tablets. The label shows a quantity of 500 tablets and is distributed by ANI Pharmaceuticals, Inc. It includes storage instructions, pharmacist guidance, manufacturer details from Esjay Pharma Private Limited, India, and a warning to keep medication out of children's reach.*

FDA Label Image

Structure (Structure)

Chemical structure of oxcarbazepine, depicting its molecular framework including a dibenzazepine core with a ketone group and a carbamoyl substituent.*

FDA Label Image

Table-1 (Table 1)

This text panel lists side effects associated with Oxcarbazepine, including nausea, tiredness (lack of energy), headache, confusion, and more frequent or severe seizures. It appears to be part of a patient information or warning section for oral film-coated Oxcarbazepine tablets by ANI Pharmaceuticals.*

FDA Label Image

Table-2 (Table 2)

A partial Drug Facts or warning text panel listing potential side effects or adverse reactions associated with medication use. The text includes symptoms such as swelling of the face, eyes, lips, or tongue; trouble swallowing or breathing; skin rash; hives; fever; swollen glands; painful sores in or around the mouth or eyes; yellowing of the skin or eyes; unusual bruising or bleeding; severe fatigue or weakness; severe muscle pain; and frequent infections that do not go away.*

FDA Label Image

Table-3 (Table 3)

A text panel listing potential behavioral and mood-related side effects associated with the medication Oxcarbazepine. It includes symptoms such as thoughts about suicide, new or worsening depression and anxiety, panic attacks, insomnia, irritability, aggression, dangerous impulses, mania, and other unusual changes in behavior or mood.*

FDA Label Image

Table-4 (Table 4)

A text panel listing side effects including dizziness, sleepiness, double vision, tiredness, nausea, vomiting, vision problems, trembling, unsteady walking and coordination, and rash. This panel is likely part of the safety or warnings information for Oxcarbazepine tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.